Bernadette Jeremiasse

56 timestamped statements across 2 topics — auto-found in recorded discussions, each timestamp jumps to the exact moment.

Featured statements

▶ Ep 2 · 0:12
Achieving complete tumor resections without major complications remains challenging. Some tumors, it's difficult to distinguish tumorous tissue from healthy, and in other tumors, the margin is very narrow.
quote · Breast Cancer
▶ Ep 2 · 1:50
The main advantages of organoids is that they maintain molecular tumor characteristics and can be held in culture for a long time.
quote · Breast Cancer
▶ Ep 420 · 6:45
These probes resulted in TBRs, tumor to background ratios above 2, indicating good intraoperative visibility.
quote · Pediatric Oncology
▶ Ep 420 · 5:25
The intensity of the tumor organoid must be at least twice the fluorescence of the healthy control organoid.
quote · Pediatric Oncology

Nothing matches these filters — clear the search or widen the filters.

Bernadette's statements about Breast Cancer 28 statements

Open the Breast Cancer collection →

BOB Ped Surg 2023 - Bernadette Jeremiasse, IPSO - Presentation

▶ Ep 2 · 0:12
clinical Achieving complete tumor resections without major complications remains challenging because some tumors are difficult to distinguish from healthy tissue and in other tumors the margin is very narrow. ↗
▶ Ep 2 · 0:12
quote Achieving complete tumor resections without major complications remains challenging. Some tumors, it's difficult to distinguish tumorous tissue from healthy, and in other tumors, the margin is very narrow. ↗
▶ Ep 2 · 0:50
clinical Fluorescence guided surgery with tumor-specific probes can visually assist the surgeon in discriminating tumors from healthy tissue. ↗
▶ Ep 2 · 1:10
clinical Tumor-specific probes are currently screened one by one and per tumor type. ↗
▶ Ep 2 · 1:25
clinical The imaging platform combines tumor organoid biobanks with 3D live imaging and is able to screen fluorescent guided surgery probes in a tumor-specific and patient-specific way. ↗
▶ Ep 2 · 1:50
quote The main advantages of organoids is that they maintain molecular tumor characteristics and can be held in culture for a long time. ↗
▶ Ep 2 · 1:50
clinical Organoids maintain molecular tumor characteristics and can be held in culture for a long time. ↗
▶ Ep 2 · 2:05
clinical The platform uses both adult and pediatric tumor organoid biobanks, specifically neuroblastoma and breast cancer. ↗
▶ Ep 2 · 2:20
clinical Control organoids were chosen based on the tissue surrounding the tumor: kidney organoids for neuroblastoma and healthy breast organoids for breast cancer. ↗
▶ Ep 2 · 3:00
clinical Surface markers upregulated in neuroblastoma or breast cancer were identified based on RNA profiling, the human protein atlas, and literature review. ↗
▶ Ep 2 · 3:20
clinical Probes targeting surface markers were conjugated to six different fluorophores ranging between 488 and 647 nanometers. ↗
▶ Ep 2 · 3:35
clinical Seven-colored 3D live imaging using confocal microscopy on living organoids was performed, including six probe fluorophores plus the general marker eFluor. ↗
▶ Ep 2 · 3:55
clinical Segmentation analysis was performed using the STAPLE pipeline developed in the laboratory, and fluorescent signals were quantified. ↗
▶ Ep 2 · 4:10
clinical The three most promising probes for neuroblastoma were validated in vivo using a mouse xenograft model with tumors originating from neuroblastoma organoids. ↗
▶ Ep 2 · 4:40
clinical Probe fluorescence varies between patients and even within a patient in neuroblastoma organoid lines. ↗
▶ Ep 2 · 4:55
clinical Different probes work on tumor organoids compared to healthy control organoids. ↗
▶ Ep 2 · 5:05
clinical The STAPLE pipeline performs 3D segmentation by first segmenting membrane and nuclear signals, generating cells, and combining cells to form single organoids. ↗
▶ Ep 2 · 5:25
clinical An organoid is determined to be positive when the intensity of the tumor organoid is at least twice the fluorescence of the healthy control organoid. ↗
▶ Ep 2 · 5:25
quote The intensity of the tumor organoid must be at least twice the fluorescence of the healthy control organoid. ↗
▶ Ep 2 · 5:35
clinical One of the tested probes is advancing to a clinical trial this year. ↗
▶ Ep 2 · 5:35
clinical The order of neuroblastoma organoid line performance was similar in vitro and in vivo, with line 129 being highest and line 67 being lowest. ↗
▶ Ep 2 · 5:45
clinical Thousands of organoids were quantified using this methodology. ↗
▶ Ep 2 · 5:55
clinical Four markers showed promise for neuroblastoma based on high percentages of positive organoids and high fluorescent intensities. ↗
▶ Ep 2 · 6:15
clinical The platform can predict which combinations of probes are most promising by screening six probes simultaneously. ↗
▶ Ep 2 · 6:30
clinical The three most promising probes tested in vivo for neuroblastoma were GD2, L1CAM, and NCAM. ↗
▶ Ep 2 · 6:45
clinical These three probes resulted in tumor-to-background ratios above 2, indicating good intraoperative visibility. ↗
▶ Ep 2 · 6:45
quote These probes resulted in TBRs, tumor to background ratios above 2, indicating good intraoperative visibility. ↗
▶ Ep 2 · 7:00
clinical In vitro imaging patterns resemble the efficacy in vivo, with L1CAM showing higher signal than GD2 in both settings. ↗
Bernadette's statements about Pediatric Oncology 28 statements

Open the Pediatric Oncology collection →

BOB Ped Surg 2023 - Bernadette Jeremiasse, IPSO - Presentation

▶ Ep 420 · 0:12
quote Achieving complete tumor resections without major complications remains challenging. Some tumors, it's difficult to distinguish tumorous tissue from healthy, and in other tumors, the margin is very narrow. ↗
▶ Ep 420 · 0:12
clinical Achieving complete tumor resections without major complications remains challenging because some tumors are difficult to distinguish from healthy tissue and in other tumors the margin is very narrow. ↗
▶ Ep 420 · 0:50
clinical Fluorescence guided surgery with tumor-specific probes can visually assist the surgeon in discriminating tumors from healthy tissue. ↗
▶ Ep 420 · 1:10
clinical Tumor-specific probes are currently screened one by one and per tumor type. ↗
▶ Ep 420 · 1:25
clinical The imaging platform combines tumor organoid biobanks with 3D live imaging and is able to screen fluorescent guided surgery probes in a tumor-specific and patient-specific way. ↗
▶ Ep 420 · 1:50
quote The main advantages of organoids is that they maintain molecular tumor characteristics and can be held in culture for a long time. ↗
▶ Ep 420 · 1:50
clinical Organoids maintain molecular tumor characteristics and can be held in culture for a long time. ↗
▶ Ep 420 · 2:05
clinical The platform uses both adult and pediatric tumor organoid biobanks, specifically neuroblastoma and breast cancer. ↗
▶ Ep 420 · 2:20
clinical Control organoids were chosen based on the tissue surrounding the tumor: kidney organoids for neuroblastoma and healthy breast organoids for breast cancer. ↗
▶ Ep 420 · 3:00
clinical Surface markers upregulated in neuroblastoma or breast cancer were identified based on RNA profiling, the human protein atlas, and literature review. ↗
▶ Ep 420 · 3:20
clinical Probes targeting surface markers were conjugated to six different fluorophores ranging between 488 and 647 nanometers. ↗
▶ Ep 420 · 3:35
clinical Seven-colored 3D live imaging using confocal microscopy on living organoids was performed, including six probe fluorophores plus the general marker eFluor. ↗
▶ Ep 420 · 3:55
clinical Segmentation analysis was performed using the STAPLE pipeline developed in the laboratory, and fluorescent signals were quantified. ↗
▶ Ep 420 · 4:10
clinical The three most promising probes for neuroblastoma were validated in vivo using a mouse xenograft model with tumors originating from neuroblastoma organoids. ↗
▶ Ep 420 · 4:40
clinical Probe fluorescence varies between patients and even within a patient in neuroblastoma organoid lines. ↗
▶ Ep 420 · 4:55
clinical Different probes work on tumor organoids compared to healthy control organoids. ↗
▶ Ep 420 · 5:05
clinical The STAPLE pipeline performs 3D segmentation by first segmenting membrane and nuclear signals, generating cells, and combining cells to form single organoids. ↗
▶ Ep 420 · 5:25
quote The intensity of the tumor organoid must be at least twice the fluorescence of the healthy control organoid. ↗
▶ Ep 420 · 5:25
clinical An organoid is determined to be positive when the intensity of the tumor organoid is at least twice the fluorescence of the healthy control organoid. ↗
▶ Ep 420 · 5:35
clinical The order of neuroblastoma organoid line performance was similar in vitro and in vivo, with line 129 being highest and line 67 being lowest. ↗
▶ Ep 420 · 5:35
clinical One of the tested probes is advancing to a clinical trial this year. ↗
▶ Ep 420 · 5:45
clinical Thousands of organoids were quantified using this methodology. ↗
▶ Ep 420 · 5:55
clinical Four markers showed promise for neuroblastoma based on high percentages of positive organoids and high fluorescent intensities. ↗
▶ Ep 420 · 6:15
clinical The platform can predict which combinations of probes are most promising by screening six probes simultaneously. ↗
▶ Ep 420 · 6:30
clinical The three most promising probes tested in vivo for neuroblastoma were GD2, L1CAM, and NCAM. ↗
▶ Ep 420 · 6:45
clinical These three probes resulted in tumor-to-background ratios above 2, indicating good intraoperative visibility. ↗
▶ Ep 420 · 6:45
quote These probes resulted in TBRs, tumor to background ratios above 2, indicating good intraoperative visibility. ↗
▶ Ep 420 · 7:00
clinical In vitro imaging patterns resemble the efficacy in vivo, with L1CAM showing higher signal than GD2 in both settings. ↗